BLEG (Branded Legacy) Debt-to-EBITDA : -0.91 (As of Dec. 2021)

What is Branded Legacy Debt-to-EBITDA?

Branded Legacy BLEG Debt-to-EBITDA is -0.91 as of Dec. 2021.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Branded Legacy's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $0.01 Mil. Branded Legacy's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $0.42 Mil. Branded Legacy's annualized EBITDA for the quarter that ended in Dec. 2021 was $-0.48 Mil. Branded Legacy's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 was -0.91.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Branded Legacy's Debt-to-EBITDA or its related term are showing as below:

BLEG's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.68
* Ranked among companies with meaningful Debt-to-EBITDA only.

Branded Legacy (OTCPK:BLEG) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Branded Legacy Debt-to-EBITDA Related Terms

Branded Legacy Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Branded Legacy's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Branded Legacy Debt-to-EBITDA Chart

Branded Legacy Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-EBITDA

Get a 7-Day Free Trial

-1.00

-0.07

-0.11

-0.53

-1.39

Branded Legacy Quarterly Data
	Dec15	Dec16	Dec17	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Debt-to-EBITDA	Get a 7-Day Free Trial												-0.36	-1.08	-0.75	-2.47	-0.91

BLEG vs UPDC, RIBT, GDMK: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Branded Legacy's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Branded Legacy Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Branded Legacy's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Branded Legacy's Debt-to-EBITDA falls into.

Save Embed

Branded Legacy Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Branded Legacy's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.014	+	0.421)	/	-0.314
	=	-1.39

Branded Legacy's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.014	+	0.421)	/	-0.476
	=	-0.91

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2021) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →

What does a Debt-to-EBITDA of -0.91 mean?

Branded Legacy (BLEG) has a Debt-to-EBITDA of -0.91 as of Dec. 2021. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Branded Legacy.

Is Branded Legacy's Debt-to-EBITDA too high?

Branded Legacy's current Debt-to-EBITDA is -0.91.

How does Branded Legacy's Debt-to-EBITDA compare to UPDC and RIBT?

Branded Legacy's Debt-to-EBITDA of -0.91 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-EBITDA for a Drug Manufacturers company?

The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-EBITDA mean?

A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Branded Legacy. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Branded Legacy's current Debt-to-EBITDA is -0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Branded Legacy stock overvalued right now?

Branded Legacy (BLEG) has a current Debt-to-EBITDA of -0.91. The current Debt-to-EBITDA is -0.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-EBITDA calculated?

Debt-to-EBITDA is calculated from a company's financial statements. For Branded Legacy (BLEG), the current Debt-to-EBITDA is -0.91 as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Branded Legacy Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies UPDC RIBT GDMK SHRG TOFB CYAN BABB HBISD RTON CLXT XSWX:NESN SHSE:603288 GIS KHC XPAR:BN SZSE:300999 SHSE:600887 HRL K NSE:NESTLEIND

Address 751 North Drive, Suite 9, Melbourne, FL, USA, 32934

Website https://www.brandedlegacy.com

Branded Legacy Inc provides high-level strategic advisory and operational transformation services focused on complex research, clinical development, and data-intensive organizations. Branded Legacy specializes in supporting large-scale international research consortia, platform clinical trials, and institutional/government data science initiatives. The core operations center on diagnosing operational inefficiencies, redesigning legacy systems, and implementing transparent, high-impact solutions that deliver measurable results.